In a recent study, DPP-4 inhibitors are suggested for hospitalized COVID-19 patients suffering from diabetes [19], but the use of sulfonylureas and metformin against SARS-CoV-2-infected diabetic patients is still controversial [20]. This evidence concerns the gene DPP4 and COVID-19.